Sight Sciences, Inc. (SGHT) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Sight Sciences, Inc. (SGHT) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Seeking Alpha • May 14, 2026

Sight Sciences, Inc. (SGHT) Q1 2026 Earnings Call Transcript

Sight Sciences, Inc. (SGHT) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 7, 2026

Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance

MENLO PARK, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2026 and raised its revenue guidance for full year 2026.

GlobeNewsWire • May 6, 2026

Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Beats Revenue Estimates

Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.28 per share a year ago.

Zacks Investment Research • May 6, 2026

Sight Sciences (SGHT) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Sight Sciences (SGHT) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • May 7, 2026

Sight Sciences to Present at Two Upcoming Investor Conferences

MENLO PARK, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at two upcoming conferences.

GlobeNewsWire • Apr 29, 2026

Sight Sciences Announces the Release of its Sustainability Report

The Sustainability Report provides data for 2023 through 2025 on the Company's environmental, social, and governance initiatives The Sustainability Report provides data for 2023 through 2025 on the Company's environmental, social, and governance initiatives

GlobeNewsWire • Apr 22, 2026

Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026

MENLO PARK, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2026, after the market close on Wednesday, May 6, 2026. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

GlobeNewsWire • Apr 21, 2026

Sight Sciences' Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

MENLO PARK, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that data on two of its proprietary glaucoma and dry eye technologies, the OMNI® Surgical System and the TearCare® System, will be presented at this year's ASCRS Annual Meeting held in Washington, DC.

GlobeNewsWire • Apr 1, 2026

Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury's Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent

Court preserves jury's finding of willful infringement by Alcon, and awards past damages to Sight Sciences in excess of $34 million and ongoing royalties through November 2028 Court preserves jury's finding of willful infringement by Alcon, and awards past damages to Sight Sciences in excess of $34 million and ongoing royalties through November 2028

GlobeNewsWire • Mar 30, 2026